ARGX argenx SE

941.27USD858.20 EUR · EBR-0.14%Mkt Cap: 59.19B USDP/E: 34.54

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART fo…

Institutional holders11 on file

Key Statistics

Company
Market Cap59.19B USD
Enterprise Value53.23B USD
Revenue (TTM)5.92B USD
Gross Profit3.70B USD
Net Income (TTM)1.29B USD
Revenue/Share95.08 USD
Last Price941.27 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.9K
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINNL0010832176
Valuation
P/E (Trailing)34.54
P/E (Forward)26.81
PEG1.28
EV/EBITDA25.53
EV/Revenue9.00
P/S9.12
P/B7.16
EPS (TTM)24.85 USD
EPS (Forward)32.01 USD
52W Range
623.4281% of range1014.54
52W High1014.54 USD
52W Low623.42 USD
Profitability
Gross Margin89.15%
Oper. Margin31.94%
EBITDA Margin32.14%
Profit Margin31.11%
ROE17.64%
ROA14.88%
ROIC35.99%
ROCE14.32%
Growth
Revenue Growth52.10%
Earnings Growth50.60%
Cash Flow & Leverage
Operating CF685.19M USD
CapEx (TTM)111.68M USD
FCF Margin—
FCF Yield—
Net Debt-5.14B USD
Net Debt/EBITDA-2.70
Net Debt/FCF—
Balance Sheet
Debt/Equity0.01
Current Ratio—
Quick Ratio—
Book Value/Sh119.80 USD
Cash/Share82.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1118.09 USD
Upside (mean)+18.8%
Target Range869.39 USD – 1348.90 USD
869.39+18.8% to mean1348.90
# Analysts15
Ownership
Shares Out.62.89M
Float62.43M
Insiders0.00%
Institutions49.31%
Technical
SMA 50896.45 (+5.0%)
SMA 200824.49 (+14.2%)
Beta-0.06
S&P 52W Chg12.00%
Avg Vol (30d)95.19K
Avg Vol (10d)91.40K
Technical Indicators
RSI (14)58.9
MACD19.3471
MACD Signal15.4457
MACD Hist.+3.9013
BB Upper992.85 USD
BB Middle909.28 USD
BB Lower825.71 USD
BB Width18.38%
ATR (14)27.41 USD
Vol Ratio (20d)0.71x

About argenx (EBR: ARGX)

›

argenx (EBR: ARGX) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,863 employees.

The shares were at 858.20 EUR on 19 November 2026, up 7.6% over 52 weeks. Its 52-week range is 568.40 EUR to 925.00 EUR: the price is 7.2% below the high and 51.0% above the low.

At a market capitalisation of 53.97B EUR, it trades at 34.5 times trailing earnings and 26.8 times forward earnings. The median trailing P/E of its 12 largest Biotechnology peers is 38.7, a discount of 11% for ARGX.

argenx reports return on equity of 17.6%, an operating margin of 31.9% and revenue up 52.1% year over year.

It holds more cash than debt, a net cash position of 5.14B USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 1019.41 EUR is 18.8% above the current price. The next earnings report is expected on 25 February 2027.